AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph at page 13, spanning lines 7 – 12 as follows.

In the experiments described herein, the prevalence of inhibitor development in a murine model of hemophilia which is caused by a large deletion affecting the promoter region and exons 1-3 of the F.IX gene ~~(Blood 90:3962)~~ (Lin *et al.*, 1997, A Coagulation Factor IX-Deficient Mouse Model for Human Hemophilia B, Blood, 90:3962–3966) was assessed. This results in an absence of F.IX transcript and protein. The second aim of the study was to evaluate the effect of immunomodulation in reducing the risk of inhibitor development.